PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
出版年份 2016 全文链接
标题
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 115, Issue 10, Pages 1157-1173
出版商
Springer Nature
发表日期
2016-10-14
DOI
10.1038/bjc.2016.311
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety
- (2016) U. A. Matulonis et al. ANNALS OF ONCOLOGY
- Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- (2016) Yvette Drew et al. BRITISH JOURNAL OF CANCER
- Abstract CT011: Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies
- (2016) Zev A. Wainberg et al. CANCER RESEARCH
- Vorwort
- (2016) J Sehouli GEBURTSHILFE UND FRAUENHEILKUNDE
- Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
- (2016) Susan M. Domchek et al. GYNECOLOGIC ONCOLOGY
- An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
- (2016) J. Mateo et al. Targeted Oncology
- The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
- (2015) Jing Huang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
- (2015) Vasiliki Michalarea et al. CANCER RESEARCH
- Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
- (2015) Ursula A. Matulonis et al. CANCER RESEARCH
- 317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies
- (2015) Z.A. Wainberg et al. EUROPEAN JOURNAL OF CANCER
- 458 DNA repair deficiencies in ovarian cancer: Genomic analysis of high grade serous ovarian tumors from the NOVA study
- (2015) K. Timms et al. EUROPEAN JOURNAL OF CANCER
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- PARP inhibitors for anticancer therapy
- (2014) Nicola Curtin BIOCHEMICAL SOCIETY TRANSACTIONS
- Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
- (2014) G Del Conte et al. BRITISH JOURNAL OF CANCER
- New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances
- (2014) J. Liu et al. CLINICAL CANCER RESEARCH
- 215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib
- (2014) E. Swisher et al. EUROPEAN JOURNAL OF CANCER
- 214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer
- (2014) P. Haluska et al. EUROPEAN JOURNAL OF CANCER
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
- (2014) Julie K. Horton et al. MOLECULAR CANCER RESEARCH
- Abstract A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.
- (2014) G. Shapiro et al. MOLECULAR CANCER THERAPEUTICS
- Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining
- (2014) Aashish Soni et al. NUCLEIC ACIDS RESEARCH
- Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway
- (2014) C. Gorrini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2
- (2014) A. R. Venkitaraman SCIENCE
- PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
- (2014) Y. Hu et al. Cancer Discovery
- PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
- (2013) J.-m. Lee et al. ANNALS OF ONCOLOGY
- Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
- (2013) Mo Li et al. CANCER CELL
- Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
- (2013) J. E. Ang et al. CLINICAL CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
- (2013) Chiara Gorrini et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- New perspectives in ovarian cancer treatment
- (2013) Bernd C. Schmid et al. MATURITAS
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
- (2013) J. Ross Chapman et al. MOLECULAR CELL
- A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice
- (2013) Cristina Escribano-Díaz et al. MOLECULAR CELL
- 53BP1 Regulates DSB Repair Using Rif1 to Control 5' End Resection
- (2013) M. Zimmermann et al. SCIENCE
- Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
- (2013) M. Di Virgilio et al. SCIENCE
- Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
- (2013) Smita Bhatia SEMINARS IN ONCOLOGY
- The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
- (2013) Silvana B. De Lorenzo et al. Frontiers in Oncology
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- PARPs and the DNA damage response
- (2012) F. G. Sousa et al. CARCINOGENESIS
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases
- (2012) Markus Hassler et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rules of engagement for base excision repair in chromatin
- (2012) Ian D. Odell et al. JOURNAL OF CELLULAR PHYSIOLOGY
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitative Live Cell Imaging Reveals a Gradual Shift between DNA Repair Mechanisms and a Maximal Use of HR in Mid S Phase
- (2012) Ketki Karanam et al. MOLECULAR CELL
- Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
- (2012) J. Ross Chapman et al. MOLECULAR CELL
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- Double-Strand Break End Resection and Repair Pathway Choice
- (2011) Lorraine S. Symington et al. Annual Review of Genetics
- Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
- (2011) Timothy A. Yap et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications
- (2011) S. E. Polo et al. GENES & DEVELOPMENT
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins
- (2011) A. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
- (2011) Stuart L. Rulten et al. MOLECULAR CELL
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- The MRE11 complex: starting from the ends
- (2011) Travis H. Stracker et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway
- (2010) Michael R. Lieber Annual Review of Biochemistry
- Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
- (2010) N. Chan et al. CANCER RESEARCH
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
- (2010) C. E. Strom et al. NUCLEIC ACIDS RESEARCH
- PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
- (2009) Helen E Bryant et al. EMBO JOURNAL
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination
- (2009) Isabelle Robert et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
- (2009) Susan J. Ramus et al. Molecular Oncology
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research
- (2008) Susan L. Neuhausen et al. BREAST CANCER RESEARCH AND TREATMENT
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- Single-strand break repair and genetic disease
- (2008) Keith W. Caldecott NATURE REVIEWS GENETICS
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect ofBRCA1/2Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer
- (2007) Angela Chetrit et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started